However, in a CKD mouse model where FGF23 cleavage is reduced, EPO injection caused an increase in the iFGF23 with the reduced percentage of iFGF23 relative to total FGF23, indicating that EPO stimulates FGF23 cleavage in CKD [59]. Here, EPO is linked to chronic kidney disease.